Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IL18 | Q14116 | 1/20 | 0.42 |
| ▸ | PFKFB1 | P16118 | 3/20 | 0.42 |
| ▸ | PFKFB2 | O60825 | 2/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437996 | 1.00 | AR (0.55) | ARALDH1A1IMPDH2IMPDH1PLA2G7 | |
| SCHEMBL17554785 | 0.90 | AR (0.46) | ARALDH1A1IMPDH2IMPDH1PLA2G7 | |
| SCHEMBL12594099 | 0.88 | PFKFB2 (0.44) | ARALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL21908141 | 0.87 | AR (0.54) | ARALDH1A1IMPDH2IMPDH1PLA2G7 | |
| SCHEMBL13832485 | 0.86 | AR (0.45) | ARALDH1A1IMPDH2METAXL | |
| SCHEMBL13721442 | 0.85 | AR (0.55) | ARALDH1A1IMPDH2IMPDH1PLA2G7 | |
| SCHEMBL13832555 | 0.84 | AR (0.50) | ARALDH1A1IMPDH2IMPDH1PLA2G7 | |
| SCHEMBL12595082 | 0.83 | BRAF (0.47) | ALDH1A1METMTNR1AMTNR1BS1PR4 | |
| SCHEMBL17351035 | 0.82 | AR (0.59) | ARALDH1A1IMPDH2KDM4EPOLB | |
| SCHEMBL15671647 | 0.82 | AR (0.46) | ARALDH1A1IMPDH2IMPDH1PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUCTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| US-9216967-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| EP-2509961-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | Autifony Therapeutics Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | AR 4850/4885ALDH1A1 1966/4885IMPDH2 2258/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | AR 4850/4885ALDH1A1 1966/4885IMPDH2 2258/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | AR 4850/4885ALDH1A1 1966/4885IMPDH2 2258/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | AR 4780/4885ALDH1A1 848/4885IMPDH2 1230/4885 |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | AR 4850/4885ALDH1A1 1966/4885IMPDH2 2258/4885 |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | AR 4780/4885ALDH1A1 848/4885IMPDH2 1230/4885 |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNA3, KCND3, KCNN3 | AR 4863/4885ALDH1A1 1789/4885IMPDH2 2536/4885 |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | AR 4638/4885ALDH1A1 462/4885IMPDH2 897/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | AR 4863/4885ALDH1A1 1789/4885IMPDH2 2536/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | AR 4850/4885ALDH1A1 1966/4885IMPDH2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.